Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
Phase 4
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT01094184
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 95
- Registration Number
- NCT01089023
Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 201
- Registration Number
- NCT01089413
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
Phase 3
Completed
- Conditions
- Hepatitis D, Chronic
- Interventions
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01088659
- Locations
- 🇹🇷
Dokuz Eylul University Medical Faculty; Infection, Izmir, Turkey
🇹🇷Istanbul Uni Cerrahpasa Medical Faculty; Gastroenterolgy, Istanbul, Turkey
🇹🇷Ankara University Medical Facility; Hepatology Department, Ankara, Turkey
A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Device: AutoinjectorDevice: Pre-filled syringe
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT01087944
A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [PEGASYS]
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 265
- Registration Number
- NCT01086085
A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT01077726
A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 75
- Registration Number
- NCT01077739
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 86
- Registration Number
- NCT01077713
An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 151
- Registration Number
- NCT01075477
© Copyright 2025. All Rights Reserved by MedPath